Catyalyst Pharma (CPRX) Reports In-Line Q4 EPS

Catyalyst Pharma (NASDAQ: CPRX) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07).

For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
• reAlpha Tech Corp. (AIRE) Misses Q2 EPS by 7c